VNRX - Wutah pendapatan taunan sajrone rolas wulan kepungkur volition.com

Logo grafis VolitionRx (VNRX)

Year-over-year product sales dynamics for the TTM visualize revenue growth rates, where 133.90 indicates the value of this parameter. VolitionRx Limited (VNRX) is protected by its unique Nu.Q patent portfolio and strict FDA oversight. Its status as a leading developer of epigenetic tests ensures the trust of the scientific community; however, the lack of stable cash flow leaves the company dependent on external investments.

Wutah pendapatan YoY sajrone 12 wulan kepungkur: VolitionRx Ltd (VNRX) kanggo 11.02.2024 - 18.11.2026

Ringkesan rincian data analitis VolitionRx Ltd (VNRX)

- nilai saham lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:VNRX VolitionRx Ltd.
Produk asil prodhuksi VolitionRx Ltd.

During periods of market volatility, business resilience is determined by the ability to generate a stable cash flow. VolitionRx Limited (VNRX) is scaling the implementation of Nu.Q nucleosome diagnostics within the B2B veterinary and medical segments. By analyzing the year-over-year revenue growth rate for the TTM, an investor can observe the pace of revenue increase over 12 months relative to the previous year. Smoothing out short-term fluctuations allows for the identification of the real dynamics of expansion in the diagnostics market. Steady growth in this metric confirms the effectiveness of technology commercialization.